Head and Neck Cancer News The use of proton beam therapy (PBT) increased between 2004 and 2018, particularly for cancers in which the effectiveness of PBT is still under investigation.
The risk of neurologic adverse events was 41% lower in patients treated with immune checkpoint inhibitors than in patients who received another drug regimen or a placebo.
A high neutrophil-lymphocyte ratio appears to be an independent predictor of outcomes for some patients with head and neck cancer.
The risk score can improve upon EBV-based screening, according to researchers.
Patients derived a benefit from tislelizumab regardless of PD-L1 expression, but another biomarker appears to predict benefit.
Pembrolizumab plus chemotherapy did not improve overall survival in patients with a PD-L1 combined positive score below 1.
Adding toripalimab to standard chemotherapy extended progression-free survival by 13.2 months.
Induction with paclitaxel, cisplatin, and capecitabine proved more effective than cisplatin plus fluorouracil.
Measuring lymphocytes during or after radiotherapy could provide useful information about infection risk, according to researchers.
The highest rate of non-concordant care was seen in patients with cervical cancer.
Regional relapse-free survival rates were similar with whole-neck irradiation and upper-neck irradiation.
Radioiodine after thyroidectomy did not improve outcomes in patients with low-risk thyroid cancer.
Researchers hypothesized that a rising number of thyroid cancer rates in adults with obesity in may also imply an increase in thyroid cancer rates in children.
Tisotumab vedotin demonstrated antitumor activity in relapsed, locally advanced, or metastatic squamous cell carcinoma of the head and neck.
The complete response rate in patients with cutaneous squamous cell carcinoma is unprecedented, according to an investigator.
Race, age, insurance status, and other factors were significantly associated with the receipt of advanced radiotherapy techniques.
The multimodal AI platform proved more accurate than deep learning alone.
Adding capecitabine to best supportive care prolonged progression-free survival.
The efficacy of many combination therapies may be due to independent drug action, not synergistic or additive effects.
Reducing the radiotherapy dose and target volume to subclinical regions produced “favorable clinical outcomes,” according to researchers.
Load More
